Joanna L Kaplan, Victor N Rivas, Ashley L Walker, Louise Grubb, Aisling Farrell, Stuart Fitzgerald, Susan Kennedy, Carina E Jauregui, Amanda E Crofton, Chris McLaughlin, Rachel Van Zile, Teresa C DeFrancesco, Kathryn M Meurs, Joshua A Stern
OBJECTIVE: Feline hypertrophic cardiomyopathy (HCM) remains a disease with little therapeutic advancement. Rapamycin modulates the mTOR pathway, preventing and reversing cardiac hypertrophy in rodent disease models. Its use in human renal allograft patients is associated with reduced cardiac wall thickness. We sought to evaluate the effects of once-weekly delayed-release (DR) rapamycin over 6 months on echocardiographic, biochemical, and biomarker responses in cats with subclinical, nonobstructive HCM...
July 26, 2023: Journal of the American Veterinary Medical Association